Clarivate (NYSE:CLVT) Trading Down 5.2% – Here’s Why

Clarivate PLC (NYSE:CLVT) fell 5.2% during trading on Monday . The stock traded as low as $2.27 and last traded at $2.2660. 176,625 shares changed hands during mid-day trading, a decline of 97% from the average session volume of 6,808,156 shares. The stock had previously closed at $2.39.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on CLVT. Wall Street Zen raised shares of Clarivate from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Clarivate in a research report on Wednesday, June 24th. Finally, Barclays raised their price target on shares of Clarivate from $2.40 to $2.50 and gave the stock an “underweight” rating in a research note on Tuesday, July 7th. Four investment analysts have rated the stock with a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, Clarivate has a consensus rating of “Reduce” and an average target price of $2.98.

Clarivate Stock Performance

The company has a debt-to-equity ratio of 0.89, a current ratio of 0.84 and a quick ratio of 0.84. The stock has a market cap of $1.44 billion, a price-to-earnings ratio of -10.74 and a beta of 1.38. The firm has a fifty day moving average of $2.33 and a 200 day moving average of $2.48.

Clarivate (NYSE:CLVT) last released its quarterly earnings data on Wednesday, April 29th. The company reported $0.18 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.04. The company had revenue of $585.50 million for the quarter, compared to analyst estimates of $569.50 million. Clarivate had a positive return on equity of 8.82% and a negative net margin of 5.61%.The firm’s revenue for the quarter was down 1.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.14 earnings per share. Clarivate has set its FY 2026 guidance at 0.700-0.800 EPS. As a group, sell-side analysts forecast that Clarivate PLC will post 0.65 EPS for the current year.

Institutional Investors Weigh In On Clarivate

A number of hedge funds have recently modified their holdings of CLVT. Atairos Partners GP Inc. increased its position in Clarivate by 195.3% during the fourth quarter. Atairos Partners GP Inc. now owns 10,232,667 shares of the company’s stock worth $34,177,000 after purchasing an additional 6,767,667 shares during the last quarter. First Trust Advisors LP acquired a new position in Clarivate in the 4th quarter valued at about $16,721,000. Balyasny Asset Management L.P. grew its stake in shares of Clarivate by 827.6% in the 3rd quarter. Balyasny Asset Management L.P. now owns 4,882,593 shares of the company’s stock valued at $18,700,000 after buying an additional 4,356,232 shares during the period. Bank of America Corp DE grew its stake in shares of Clarivate by 506.9% in the 2nd quarter. Bank of America Corp DE now owns 2,870,668 shares of the company’s stock valued at $12,344,000 after buying an additional 2,397,670 shares during the period. Finally, Man Group plc increased its holdings in shares of Clarivate by 228.1% during the 2nd quarter. Man Group plc now owns 3,091,139 shares of the company’s stock worth $13,292,000 after buying an additional 2,148,943 shares during the last quarter. Hedge funds and other institutional investors own 85.72% of the company’s stock.

Clarivate Company Profile

Clarivate plc is a global information and analytics company that provides insights and workflow solutions to accelerate the pace of innovation. The company delivers proprietary data, analytics, and expertise to support research and development in the life sciences, intellectual property management, academic institutions, government agencies, and corporations. Its core offerings include citation and patent databases, drug pipeline analytics, trademark research tools, regulatory compliance solutions, and market intelligence platforms.

Originally part of Thomson Reuters’ Intellectual Property & Science division, Clarivate was established as an independent entity in 2016 following a spin-off transaction.